Source: labonline.com.au --- Thursday, August 31, 2017
In Australia, around 52,000 people will be diagnosed with rare and less common (RLC) cancers in 2017, and 25,000 will die from them, according to estimates by Cancer in Australia 2017. RLC cancers are defined as those cancers that affect fewer than 1 in 12,000 people. While rare individually, collectively rare and less common cancers account for 30% of cancer diagnoses and 50% of cancer deaths in Australia, according to Garvan . There are 186 types of rare cancer from ovarian cancer to chordoma (a cancer of the spine). To improve the outcome for patients with rare cancer, Garvan has launched a nationally available Genomic Cancer Medicine Program with two main areas of focus — clinical trials matching patients to therapies and a risk-management program for families with an inherited high risk of cancer. It gives hope to patients who have exhausted other treatment options. The NSW government invested $7 million over four years into the Genomic Cancer Medicine Program as part of a bigger $24 million investment through the Sydney Genomics Collaborative. “The NSW government recognises the extraordinary potential of genomics in helping researchers better understand the role genes play in cancer risks as well as identifying new therapies to improve patient outcomes,” said NSW Minister for Health and Minister for Medical Research Brad Hazzard. The program was developed by the Garvan Institute in partnership with the NHMRC Clinical Trial ...
from Australia http://ift.tt/2eJf1UZ
No comments:
Post a Comment